Presentations made painless

Company > Coherus BioSciences Inc: Business Model, SWOT Analysis, and Competitors 2024

Coherus BioSciences Inc: Business Model, SWOT Analysis, and Competitors 2024

Published: Jan 10, 2024

Inside This Article


    In this comprehensive blog post, we delve into the intricacies of Coherus BioSciences Inc, a notable player in the biopharmaceutical industry, focusing on its business model, SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis, and competitive landscape as we project into 2024. By examining Coherus BioSciences' approach to developing biosimilars and innovative therapies, we aim to shed light on its strategic positioning, identify the challenges and opportunities it faces, and analyze how it stacks up against its competitors in the evolving healthcare sector. This analysis will provide valuable insights for investors, stakeholders, and industry observers keen on understanding Coherus BioSciences' potential trajectory in the coming years.

    ### What You Will Learn

    • Ownership and Strategic Vision: Discover who owns Coherus BioSciences Inc and the guiding principles behind its mission statement, understanding the company's core objectives and strategic aspirations.

    • Revenue Generation and Business Model: Learn about the mechanisms through which Coherus BioSciences Inc generates its revenue, coupled with a detailed explanation of its Business Model Canvas, providing insights into its operational foundations and value proposition.

    • Market Position and Competitive Analysis: Gain knowledge on Coherus BioSciences Inc's standing within the pharmaceutical industry, including an identification of its main competitors and a comprehensive SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis to understand its internal capabilities and external market challenges.

    Who owns Coherus BioSciences Inc?

    Who owns Coherus BioSciences Inc?

    When it comes to determining the ownership of a publicly traded company like Coherus BioSciences Inc, it's essential to look at both the institutional investors and individual stakeholders who have invested in the company. Coherus BioSciences, recognized for its work in the biopharmaceutical sector, particularly in biosimilars, has attracted attention from various investors interested in the healthcare and biotechnology industry.

    Institutional Investors

    A significant portion of Coherus BioSciences Inc is owned by institutional investors. These are entities such as mutual funds, pension funds, and investment firms that buy large quantities of shares. Their investments can influence the company's decisions and strategies due to the substantial voting power they might hold. Some of the top institutional investors in Coherus include well-known names in the investment world. However, the exact names and percentages of ownership can fluctuate over time due to buying and selling activities in the stock market.

    Individual Stakeholders and Insider Ownership

    Apart from institutional investors, individual stakeholders, including company insiders and retail investors, also own shares of Coherus BioSciences. Insider ownership is particularly noteworthy as it involves shares held by the company's executives, board members, and employees. High insider ownership can be a sign of the company's leaders believing in the business and its future success. Retail investors, although typically holding smaller shares individually compared to institutional investors, collectively contribute to the company's shareholder base.

    Public Shares

    The remainder of Coherus BioSciences's shares is owned by the general public. These are individuals and small investors who purchase stock through brokerages and trading platforms. Public shareholders, while individually holding minor sway over company decisions, collectively play a vital role in the company's market valuation and liquidity.

    In conclusion, the ownership of Coherus BioSciences Inc is a mix of institutional investors, company insiders, and the general public. This diverse shareholder base reflects a common structure for public companies, where various stakeholders have a vested interest in the company's performance and future. Understanding who owns Coherus BioSciences is crucial for investors considering a stake in the company, as it can provide insights into the company's governance, stability, and potential for growth.

    What is the mission statement of Coherus BioSciences Inc?

    Coherus BioSciences Inc., a leading biopharmaceutical company, has firmly established its mission statement as a guiding principle for its operations and strategic decisions. The company's mission is centered around making a significant impact in the lives of patients by providing affordable, high-quality biologic therapeutics. This mission is the cornerstone of their commitment to innovation, accessibility, and patient care.

    The Core of the Mission

    At the heart of Coherus BioSciences Inc.'s mission is the drive to "improve patient lives by expanding access to life-changing biologic medicines." This statement reflects the company's dedication not only to developing advanced therapeutic options but also to ensuring these options are accessible to the patients who need them most. It underscores a commitment to affordability without compromising on quality, a balance that is crucial in the pharmaceutical industry.

    How the Mission Shapes Operations

    The mission of Coherus BioSciences Inc. is not just a statement on paper; it actively shapes the company's operations and strategic focus. By prioritizing the development of biosimilars and novel biologics, Coherus aims to disrupt the traditional high-cost structure of the pharmaceutical industry. This approach allows them to offer more cost-effective solutions to healthcare providers and patients, thereby increasing access to essential medications.

    The Impact of the Mission

    The impact of Coherus BioSciences Inc.'s mission is far-reaching. It not only influences the company's research and development focus but also its partnerships, collaborations, and business model. By aligning itself with partners who share a similar vision, Coherus can amplify its impact, driving change across the healthcare landscape. The company's dedication to its mission has the potential to set new standards for affordability and access in the biopharmaceutical industry, ultimately leading to better patient outcomes and a more sustainable healthcare system.

    Looking Forward

    As Coherus BioSciences Inc. continues to grow and evolve, its mission remains a constant beacon, guiding its efforts to innovate and expand its portfolio of products. The company's commitment to its mission is evident in its strategic decisions, research initiatives, and the positive feedback from the communities it serves. Looking forward, Coherus BioSciences Inc. is poised to continue making significant strides towards fulfilling its mission, with the ultimate goal of transforming patient care through accessible biologic therapies.

    How does Coherus BioSciences Inc make money?

    How does Coherus BioSciences Inc make money?

    Coherus BioSciences Inc, a biopharmaceutical company, has carved a niche for itself in the competitive pharmaceutical industry by focusing primarily on biosimilars. Biosimilars are essentially biologic medical products that are highly similar to an already FDA-approved biologic, known as the reference product, but are typically more affordable. This strategic focus enables Coherus to tap into the growing demand for cost-effective therapeutic alternatives in the healthcare sector.

    Biosimilar Development and Sales

    The core revenue stream for Coherus BioSciences comes from the development, approval, and commercialization of biosimilars. The process begins with rigorous research and development (R&D) to ensure the biosimilar matches the reference product in terms of safety, potency, and efficacy. Following successful clinical trials and regulatory approvals, Coherus then manufactures and markets these biosimilars, both in the United States and internationally, depending on their strategic partnerships and regulatory permissions.

    A significant portion of their income is generated through the sales of these approved biosimilars. The company focuses on biosimilars for high-cost biologics in the fields of oncology, immunology, and ophthalmology among others, offering healthcare providers and patients more accessible treatment options at a lower cost. This approach not only meets a critical market need but also fuels the company's revenue growth.

    Licensing Agreements and Partnerships

    In addition to direct sales, Coherus BioSciences also engages in strategic alliances and licensing agreements with other pharmaceutical companies. These partnerships often involve sharing the development costs and responsibilities for bringing a biosimilar to market, in exchange for a share of the future profits or upfront payments and milestones. Such collaborations enable Coherus to leverage the expertise and resources of its partners, potentially accelerating the development process and expanding the market reach of its biosimilars.

    Intellectual Property and Royalties

    Another revenue stream for Coherus comes from its intellectual property (IP) portfolio. The company invests in developing proprietary technologies and processes that can make the development and production of biosimilars more efficient and cost-effective. By patenting these innovations, Coherus can license them to other companies in the biopharmaceutical industry, generating royalty income. This aspect of their business model not only diversifies their revenue sources but also underscores the value of innovation in the biosimilar space.

    In conclusion, Coherus BioSciences Inc makes money through a multi-faceted approach centered around the development and sale of biosimilars, strategic partnerships and licensing agreements, and leveraging their intellectual property portfolio. This strategy allows them to contribute significantly to making healthcare more affordable while ensuring sustainable business growth.

    Coherus BioSciences Inc Business Model Canvas Explained

    In today's rapidly evolving biopharmaceutical landscape, understanding the strategic approach of key players is crucial. Coherus BioSciences Inc, a leading name in the biosimilar market, offers a fascinating case study. Through the lens of the Business Model Canvas (BMC), we can dissect and comprehend the multifaceted nature of Coherus BioSciences' business strategy. This model offers a holistic view of the company's approach to creating, delivering, and capturing value. Let's delve into the intricacies of Coherus BioSciences Inc's Business Model Canvas.

    Key Partners

    Coherus BioSciences has strategically aligned itself with a variety of partners to bolster its market position. These include development partners, manufacturing organizations, and marketing collaborators. By aligning with experienced entities in biologics development, Coherus ensures that its biosimilars are of the highest quality and can be brought to market efficiently.

    Key Activities

    The core activities of Coherus BioSciences revolve around the development, licensing, and commercialization of biosimilar treatments. The company focuses on a targeted portfolio, emphasizing oncology and autoimmune diseases. This concentrated approach allows Coherus to leverage its expertise and resources efficiently, ensuring a streamlined development process from laboratory to market.

    Value Propositions

    Coherus BioSciences' value proposition is deeply rooted in offering cost-effective, high-quality biosimilar treatments. The company's products aim to increase accessibility to essential biologic medicines, addressing the critical issue of affordability in healthcare. By providing biosimilars that match the efficacy and safety profiles of original biologics, Coherus meets a significant need in the healthcare system.

    Customer Relationships

    Maintaining robust relationships with healthcare providers and payers is crucial for Coherus. The company invests in comprehensive support services, including patient assistance programs, to ensure its biosimilars are readily accessible. This commitment to service not only facilitates the adoption of its products but also strengthens its reputation among key stakeholders in the healthcare industry.

    Customer Segments

    The primary customers for Coherus BioSciences include healthcare providers, insurers, and pharmacy benefit managers who seek effective, more affordable biologic treatments for their constituents. By targeting these segments, Coherus ensures that its biosimilars reach the patients who stand to benefit most, particularly those in oncology and autoimmune disease areas.

    Key Resources

    Coherus BioSciences leverages its expertise in protein engineering, clinical development, and regulatory strategy as its key resources. These capabilities enable the company to navigate the complex landscape of biosimilar development and approval processes effectively. Additionally, its strategic partnerships augment these internal strengths, providing comprehensive capabilities from development through commercialization.


    Coherus BioSciences employs a multifaceted approach to distribution, utilizing direct sales teams, collaborations with healthcare providers, and agreements with pharmacy networks to ensure its biosimilars are widely available. This integrated channel strategy is designed to maximize market penetration and ensure that healthcare professionals and patients have ready access to its products.

    Cost Structure

    The primary costs for Coherus BioSciences stem from research and development, manufacturing, and marketing activities. The company focuses on controlling these expenses through strategic partnerships and efficient operational practices. By managing its cost structure carefully, Coherus can maintain competitive pricing for its biosimilars, reinforcing its value proposition.

    Revenue Streams

    Coherus BioSciences' revenue is generated primarily through the sale of its biosimilar products. The company also explores licensing agreements and partnerships as additional revenue streams. By diversifying its income sources while focusing on its core product offerings, Coherus aims to sustain and grow its financial health in the competitive biopharmaceutical market.

    Understanding Coherus BioSciences Inc through the Business Model Canvas offers valuable insights into its strategic positioning and operational focus. The company's dedication to delivering high-quality, affordable biosimilars is evident across its business model, highlighting its role in shaping the future of healthcare.

    Which companies are the competitors of Coherus BioSciences Inc?

    Coherus BioSciences Inc., a leading biotechnology company, focuses on developing and commercializing biosimilar therapies aimed at driving down healthcare costs and increasing access to important treatments. As it navigates the competitive landscape of the biopharmaceutical industry, Coherus encounters competition from various quarters. Understanding the companies that stand as competitors to Coherus BioSciences Inc. is crucial for investors, industry analysts, and other stakeholders. This section explores the main competitors of Coherus BioSciences in detail.

    Amgen Inc.

    One of the most formidable competitors of Coherus BioSciences is Amgen Inc., a multinational biopharmaceutical company known for its innovative medicines and biosimilar products. Amgen has a diverse portfolio that covers various therapeutic areas such as oncology, cardiovascular disease, and bone health, which directly competes with some of Coherus's product offerings. Amgen's strong R&D capabilities, extensive market reach, and robust pipeline of biosimilars make it a significant competitor in the biosimilar space.

    Pfizer Inc.

    Pfizer is another major player in the pharmaceutical industry, with a growing focus on biosimilars. The company's biosimilar business operates under the name Pfizer Essential Health. Pfizer has launched several biosimilars in key markets, competing directly with Coherus BioSciences in areas like oncology and inflammatory diseases. Pfizer's global presence, coupled with its vast resources and experience in drug development and commercialization, positions it as a strong competitor to Coherus.

    Sandoz (A Division of Novartis)

    Sandoz, the generics and biosimilars division of Novartis, is a pioneer in the biosimilars market, having launched the first biosimilar in Europe in 2006. Sandoz has a comprehensive portfolio of biosimilars in various stages of development and commercialization, targeting diseases such as cancer, autoimmune disorders, and endocrine conditions. With its focus on affordability and accessibility, Sandoz competes with Coherus BioSciences in striving to bring high-quality biosimilar therapies to patients worldwide.

    Mylan (Now Part of Viatris)

    Mylan, which merged with Upjohn, a division of Pfizer, to form Viatris, has been a significant competitor in the biosimilar space. Before the merger, Mylan had established a strong presence in the biosimilar market, with a focus on oncology and autoimmune diseases. The combined strength of Mylan and Upjohn under Viatris creates a larger entity with enhanced capabilities in biosimilar development and marketing, increasing competition for Coherus BioSciences.

    Teva Pharmaceutical Industries Ltd.

    Teva Pharmaceutical Industries Ltd., known primarily for its generic drug portfolio, has also ventured into the biosimilar arena. With its expertise in drug development and a global operational footprint, Teva poses competition to Coherus, especially in markets where biosimilars are gaining traction. Teva's focus on complex generics and biosimilars, along with its commitment to cost-effective healthcare solutions, aligns it as a competitor in the biosimilar landscape.

    In conclusion, Coherus BioSciences Inc. operates in a highly competitive environment, with several major pharmaceutical and biotechnology companies vying for market share in the biosimilar sector. The competition underscores the growing importance of biosimilars in improving patient access to essential therapies while managing healthcare costs. As the market evolves, staying abreast of competitive dynamics will be crucial for Coherus and its stakeholders.

    Coherus BioSciences Inc SWOT Analysis

    Coherus BioSciences Inc SWOT Analysis

    When evaluating the strategic positioning and potential future performance of Coherus BioSciences Inc, a comprehensive SWOT analysis provides valuable insights. This analysis dissects the company's internal Strengths and Weaknesses, alongside exploring external Opportunities and Threats that could influence its trajectory in the biopharmaceutical sector.


    1. Innovative Product Pipeline: Coherus BioSciences Inc has a robust pipeline of biosimilars and novel therapies, focusing on oncology and autoimmune diseases. This diversification and innovation position the company well for future growth and market penetration.

    2. Strategic Partnerships: The company has established strategic alliances and partnerships with other pharmaceutical giants. These collaborations not only enhance its R&D capabilities but also expand its market reach and distribution networks.

    3. Strong Regulatory Expertise: Coherus BioSciences has demonstrated a strong track record in navigating the complex regulatory landscape, successfully gaining FDA approvals for its biosimilar products. This expertise is a crucial asset in the highly regulated pharmaceutical industry.


    1. Dependence on Key Products: A significant portion of Coherus BioSciences' revenue is concentrated on a limited number of products. This heavy reliance could pose risks if these products face competitive pressures or regulatory challenges.

    2. Financial Constraints: As a relatively smaller player in the biopharmaceutical industry, Coherus BioSciences faces financial limitations in comparison to larger competitors. This can impact its R&D spending and marketing capabilities.

    3. Limited Global Presence: While making strides, Coherus BioSciences still has a limited presence in international markets. Expanding globally is crucial for growth but poses significant challenges and risks for the company.


    1. Expanding Biosimilar Market: The global demand for biosimilars is expected to grow significantly, driven by the need for cost-effective treatment options. Coherus BioSciences is well-positioned to capitalize on this trend with its existing and pipeline products.

    2. Strategic Acquisitions: Acquiring complementary businesses or products could offer Coherus BioSciences opportunities to diversify its portfolio and enhance its technological capabilities, driving further growth.

    3. Regulatory Changes: Favorable changes in biopharmaceutical regulations, particularly regarding biosimilar approvals, could present significant opportunities for Coherus BioSciences to expedite product launches and gain competitive advantages.


    1. Competitive Pressures: The biopharmaceutical industry is highly competitive, with numerous companies vying for market share. Increasing competition, especially in the biosimilars market, could impact Coherus BioSciences' profitability and market position.

    2. Regulatory Risks: Changes in healthcare policies and regulations, particularly in key markets like the United States and Europe, could pose challenges to Coherus BioSciences' operations and growth strategies.

    3. Intellectual Property Litigations: As with many companies in the pharmaceutical sector, Coherus BioSciences faces the risk of intellectual property litigations, which can result in financial burdens and impede product launches.

    Conducting a SWOT analysis for Coherus BioSciences Inc highlights the company's potential to navigate the biopharmaceutical industry's challenges while leveraging its strengths and opportunities for sustained growth. However, it must strategically address its weaknesses and threats to ensure long-term success and shareholder value enhancement.

    Key Takeaways

    • Ownership and Mission of Coherus BioSciences Inc.: Coherus BioSciences Inc is publicly traded, meaning its ownership is distributed among individual and institutional investors. Its mission focuses on increasing accessibility to important medications through the development and commercialization of biosimilar treatments, aiming to address both the financial and physical health needs of patients worldwide.

    • Revenue Generation: Coherus BioSciences Inc makes money primarily through the development, manufacture, and commercialization of biosimilar drugs. By offering more affordable alternatives to expensive biologic treatments, they tap into a significant market demand, ensuring a steady revenue stream from sales to healthcare providers and patients.

    • Business Model Insight: The Business Model Canvas for Coherus BioSciences Inc highlights a strategic approach centered on cost leadership in the biopharmaceutical industry. Key elements include leveraging advanced technology for efficient biosimilar production, establishing strong partnerships for distribution, and focusing on markets with high demand for affordable biologic therapeutics.

    • Competition Landscape: Coherus faces competition from both established pharmaceutical giants and emerging biotech firms in the biosimilars market. Key competitors include companies like Amgen, Pfizer, and Sandoz, which also specialize in the development and marketing of biosimilar drugs, pushing Coherus to continuously innovate and improve its offerings.

    • SWOT Analysis Overview: The SWOT analysis of Coherus BioSciences Inc reveals strengths in its focused expertise in biosimilars and strategic partnerships, opportunities in expanding global biosimilars market, weaknesses in dependency on a limited product portfolio, and threats from intense competition and regulatory hurdles. This analysis underscores the need for Coherus to leverage its strengths and opportunities while addressing its vulnerabilities and external threats to sustain growth and competitiveness in the biopharmaceutical industry.


    In conclusion, navigating the biopharmaceutical landscape reveals Coherus BioSciences Inc as a noteworthy player with a distinctive approach to ownership, mission, and revenue generation, all while operating within a competitive and challenging environment. Ownership of Coherus BioSciences Inc is vested in its shareholders, with institutional investors holding a significant portion of its equity, reflecting confidence in the company's strategic direction and leadership.

    The mission of Coherus BioSciences Inc, centered around making high-quality biologics more accessible, underscores its dedication to patient care and innovation. This commitment not only guides its operational strategies but also serves as a beacon for its research and development efforts.

    The company's revenue model, intricately linked to the development and commercialization of biosimilar and innovative drugs, showcases a sophisticated approach to navigating the biopharmaceutical sector. Through strategic partnerships, a focus on key therapeutic areas, and a commitment to cost-effectiveness, Coherus BioSciences Inc has established a solid foundation for financial sustainability and growth.

    The Business Model Canvas of Coherus BioSciences Inc further elucidates its strategic approach, emphasizing key partners, activities, resources, and value propositions. This framework provides insight into how the company positions itself to leverage opportunities within the biopharmaceutical industry effectively.

    Competitively, Coherus BioSciences Inc faces challenges from both established biopharmaceutical companies and emerging biosimilar manufacturers. The landscape is dynamic, with competitors constantly evolving in their strategies and offerings. However, Coherus's focus on biosimilars and innovative therapeutics, coupled with its strategic partnerships, positions it well to navigate these competitive waters.

    The SWOT analysis of Coherus BioSciences Inc highlights its strengths, such as a robust product pipeline and strategic partnerships, while also acknowledging weaknesses, including reliance on a limited number of products. Opportunities for growth and expansion contrast with threats from regulatory hurdles and intense competition. This analysis underscores the importance of strategic planning and adaptability in the face of an ever-changing industry landscape.

    In summary, Coherus BioSciences Inc stands out in the biopharmaceutical field through its strategic focus on biosimilars and innovative therapeutics, a clear and patient-centered mission, and a business model that emphasizes partnerships and financial sustainability. Despite facing formidable competitors and industry challenges, Coherus BioSciences Inc is well-positioned to continue making significant strides, driven by its strategic initiatives and commitment to improving patient outcomes.


    Want to create a presentation now?

    • instantly

      Instantly Create A Deck

      Let PitchGrade do this for me

    • smile

      Hassle Free

      We will create your text and designs for you. Sit back and relax while we do the work.

    Explore More Content